Naturally acquired antibody response to a Plasmodium falciparum chimeric vaccine candidate GMZ2.6c and its components (MSP-3, GLURP, and Pfs48/45) in individuals living in Brazilian malaria-endemic areas

Table 2 Prevalence of individuals presenting IgG subclass that recognizes GMZ2.6c components in studied groups

Groups	IgG1	IgG2	IgG3	IgG4
GLURP
CZS	40/46* (87%)	10/46 (21,7%)	33/46* (71,7%)	10/46 (21,7%)
ML	30/34** (88,2%)	7/34 (20,6%)	12/34 (35,3%)	6/34 (21,7%)
GJ	23/24*** (95,8%)	1/24 (4,2%)	9/24 (37,5%)	2/24 (8,3%)
MSP-3
CZS	28/31**** (90,3%)	0/31 (0%)	8/31 (25,8%)	0/31 (0%)
ML	6/7	0/7	3/7	0/7
GJ	5/5	1/5	4/5	2/5
Pfs48/45
CZS	2/2	0/2	0/2	1/2
ML	2/2	0/2	0/2	0/2
GJ	3/7	1/7	3/7	4/7

^*P < 0.0001, IgG1 and IgG3 versus IgG2 and IgG4. **P < 0.0001, IgG1 versus IgG2, IgG3 and IgG4. ***P < 0.0001, IgG1 versus IgG2 and IgG4. ****P < 0.0001, IgG1 versus IgG2, IgG3 and IgG4. Only the IgG positive samples were tested for subclasses. Prevalence of responders within and between Groups were compared by Chi-squared tests

ISSN: 1475-2875